{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T14:44:19Z","timestamp":1791557059948,"version":"4.3.4"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2019,5,1]]},"DOI":"10.1001\/jamapsychiatry.2018.4320","type":"journal-article","created":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T19:59:48Z","timestamp":1550692788000},"page":"499","source":"Crossref","is-referenced-by-count":283,"title":["Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia"],"prefix":"10.1001","volume":"76","author":[{"given":"Jari","family":"Tiihonen","sequence":"first","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland"},{"name":"Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Taipale","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland"},{"name":"School of Pharmacy, University of Eastern Finland, Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha","family":"Meht\u00e4l\u00e4","sequence":"additional","affiliation":[{"name":"EPID Research Oy, Espoo, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Vattulainen","sequence":"additional","affiliation":[{"name":"EPID Research Oy, Espoo, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Molecular Medicine, Hofstra Northwell School of Medicine, Hempstead, New York"},{"name":"Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, New York"},{"name":"Department of Child and Adolescent Psychiatry, Charit\u00e9 Universit\u00e4tsmedizin, Berlin, Germany,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antti","family":"Tanskanen","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland"},{"name":"National Institute for Health and Welfare, The Impact Assessment Unit, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"yoi180108r1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.schres.2012.03.018","article-title":"Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.","volume":"138","author":"Gallego","year":"2012","journal-title":"Schizophr Res"},{"issue":"3","key":"yoi180108r2","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.psc.2012.06.007","article-title":"Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice.","volume":"35","author":"Correll","year":"2012","journal-title":"Psychiatr Clin North Am"},{"issue":"5","key":"yoi180108r3","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1517\/14740338.2016.1165668","article-title":"Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials.","volume":"15","author":"Galling","year":"2016","journal-title":"Expert Opin Drug Saf"},{"issue":"10","key":"yoi180108r4","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1016\/j.euroneuro.2015.04.027","article-title":"Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: a nation-wide pharmacoepidemiological study.","volume":"25","author":"Sneider","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1-3","key":"yoi180108r5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.schres.2011.02.016","article-title":"Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior.","volume":"131","author":"Correll","year":"2011","journal-title":"Schizophr Res"},{"issue":"1","key":"yoi180108r6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/mp.2011.143","article-title":"Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics.","volume":"18","author":"Kishimoto","year":"2013","journal-title":"Mol Psychiatry"},{"issue":"1-3","key":"yoi180108r7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.schres.2006.08.017","article-title":"Does antipsychotic polypharmacy increase the risk for metabolic syndrome?","volume":"89","author":"Correll","year":"2007","journal-title":"Schizophr Res"},{"issue":"2","key":"yoi180108r8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/schbul\/sbn018","article-title":"Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials.","volume":"35","author":"Correll","year":"2009","journal-title":"Schizophr Bull"},{"issue":"2","key":"yoi180108r9","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1093\/schbul\/sbn030","article-title":"Does the addition of a second antipsychotic drug improve clozapine treatment?","volume":"35","author":"Barbui","year":"2009","journal-title":"Schizophr Bull"},{"issue":"1","key":"yoi180108r10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/acps.2011.125.issue-1","article-title":"Augmentation of clozapine with a second antipsychotic\u2014a meta-analysis.","volume":"125","author":"Taylor","year":"2012","journal-title":"Acta Psychiatr Scand"},{"issue":"5","key":"yoi180108r11","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1093\/schbul\/sbr004","article-title":"Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review.","volume":"38","author":"Sommer","year":"2012","journal-title":"Schizophr Bull"},{"issue":"1","key":"yoi180108r12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/wps.20387","article-title":"Antipsychotic augmentation vs monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis.","volume":"16","author":"Galling","year":"2017","journal-title":"World Psychiatry"},{"issue":"3","key":"yoi180108r13","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.psychres.2013.03.014","article-title":"Antipsychotic polypharmacy: a Japanese survey of prescribers\u2019 attitudes and rationales.","volume":"209","author":"Kishimoto","year":"2013","journal-title":"Psychiatry Res"},{"issue":"12","key":"yoi180108r14","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.4088\/JCP.11r06927","article-title":"Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach.","volume":"72","author":"Glick","year":"2011","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"yoi180108r15","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.schres.2013.10.034","article-title":"Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? a nationwide study in Hungary.","volume":"152","author":"Katona","year":"2014","journal-title":"Schizophr Res"},{"issue":"21","key":"yoi180108r16","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1203241","article-title":"Medication for attention deficit-hyperactivity disorder and criminality.","volume":"367","author":"Lichtenstein","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"yoi180108r17","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","article-title":"Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia.","volume":"74","author":"Tiihonen","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"yoi180108r18","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1093\/schbul\/sbx176","article-title":"Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia\u2014a nationwide study with 20-year follow-up.","volume":"44","author":"Taipale","year":"2018","journal-title":"Schizophr Bull"},{"key":"yoi180108r20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12911-015-0140-z","article-title":"From prescription drug purchases to drug use periods\u2014a second generation method (PRE2DUP).","volume":"15","author":"Tanskanen","year":"2015","journal-title":"BMC Med Inform Decis Mak"},{"issue":"6","key":"yoi180108r21","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1176\/appi.ajp.2011.10081224","article-title":"A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.","volume":"168","author":"Tiihonen","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"3","key":"yoi180108r22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/wps.v12.3","article-title":"Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies.","volume":"12","author":"Kane","year":"2013","journal-title":"World Psychiatry"},{"issue":"8","key":"yoi180108r23","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1176\/appi.ajp.2018.17091001","article-title":"20-Year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia.","volume":"175","author":"Tiihonen","year":"2018","journal-title":"Am J Psychiatry"},{"key":"yoi180108r24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.phrs.2017.06.002","article-title":"The effect of statins on cardiovascular outcomes by smoking status: a systematic review and meta-analysis of randomized controlled trials.","volume":"122","author":"Ursoniu","year":"2017","journal-title":"Pharmacol Res"},{"issue":"2","key":"yoi180108r25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4088\/JCP.08m04818yel","article-title":"Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study.","volume":"71","author":"Baandrup","year":"2010","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"yoi180108r26","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1001\/archgenpsychiatry.2011.1532","article-title":"Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia.","volume":"69","author":"Tiihonen","year":"2012","journal-title":"Arch Gen Psychiatry"},{"issue":"Oct","key":"yoi180108r27","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1192\/bjp.173.4.325","article-title":"Mortality in schizophrenia: antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study.","volume":"173","author":"Waddington","year":"1998","journal-title":"Br J Psychiatry"},{"issue":"Feb","key":"yoi180108r28","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1192\/bjp.188.2.122","article-title":"Schizophrenia, neuroleptic medication and mortality.","volume":"188","author":"Joukamaa","year":"2006","journal-title":"Br J Psychiatry"},{"key":"yoi180108r19","unstructured":"WHO Collaborating Center for Drug Statistics Methodology. The Anatomical Therapeutic Chemical Classification System: Structure and Principles. March 25, 2011. http:\/\/www.whocc.no\/atc\/structure_and_principles\/. Updated February 15, 2018. Accessed August 28, 2018."}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamapsychiatry\/article-pdf\/76\/5\/499\/17528665\/jamapsychiatry_tiihonen_2019_oi_180108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T15:55:40Z","timestamp":1574006140000},"score":1,"resource":{"primary":{"URL":"http:\/\/archpsyc.jamanetwork.com\/article.aspx?doi=10.1001\/jamapsychiatry.2018.4320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,1]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2018.4320","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735131895.793557870","asserted-by":"object"}]},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5,1]]}}}